Lundbeck
42.56 DKK
+0.24 %
Less than 1K followers
HLUN B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.24 %
+4.36 %
+15.09 %
-1.39 %
-7.68 %
+33.42 %
+22.79 %
+14.04 %
+73.01 %
Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.
Read moreMarket cap
42.38B DKK
Turnover
19.98M DKK
Revenue
24.63B
EBIT %
21.42 %
P/E
13.22
Dividend yield-%
2.7 %
Coverage
Latest research
Latest analysis report
Released: 24.02.2026
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
13.5
2026
Interim report Q1'26
19.8
2026
Interim report Q2'26
11.11
2026
Interim report Q3'26
All
Research
Webcasts
Press releases
ShowingAll content types
H. Lundbeck A/S: Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
H. Lundbeck A/S: Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
